SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-050881
Filing Date
2024-06-07
Accepted
2024-06-07 17:29:39
Documents
13
Period of Report
2024-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0207541-8k_tffpharma.htm   iXBRL 8-K 36693
  Complete submission text file 0001213900-24-050881.txt   212343

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tffp-20240604.xsd EX-101.SCH 3018
3 XBRL LABEL FILE tffp-20240604_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tffp-20240604_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0207541-8k_tffpharma_htm.xml XML 3788
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 241030789
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)